MedWatch(MedWatch)
FDA's program for reporting serious adverse events, product quality problems, and therapeutic inequivalence for human medical products.
Usage Examples
- A serious unexpected adverse event was reported via MedWatch within 15 calendar days.
- The sponsor submitted the annual periodic report per 21 CFR 314.80 MedWatch requirements.
- A healthcare professional submitted a voluntary MedWatch report of a device malfunction.
What is MedWatch?
MedWatch is FDA's integrated safety information and adverse event reporting program for human medical products — drugs, biologics, medical devices, dietary supplements, cosmetics, and foods. It serves two primary audiences: healthcare professionals and consumers submitting adverse event reports, and sponsors/manufacturers fulfilling mandatory reporting obligations.
MedWatch reports are the primary input to FDA's adverse event databases: FAERS (drugs and biologics), MAUDE (devices), VAERS (vaccines, run jointly with CDC). FDA analyzes reports for safety signals, conducts postmarket surveillance, and takes regulatory actions including labeling changes, Boxed Warnings, REMS requirements, and market withdrawals when indicated.
Mandatory reporting by sponsors follows specific timelines: expedited 15-day reports for serious unexpected adverse events, periodic aggregate reports (PADE, FDAAA-required postmarket studies), and MDR reports for devices. Voluntary reporting by healthcare professionals and consumers uses Form FDA 3500. Reports can be submitted online through the FDA Safety Reporting Portal, by fax, or by mail.
Regulatory Context
This term appears most often in pharmacovigilance workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 314 80, 21 CFR 803, 21 CFR 600 80.
When This Matters
- A serious unexpected adverse event was reported via MedWatch within 15 calendar days.
- The sponsor submitted the annual periodic report per 21 CFR 314.80 MedWatch requirements.
- A healthcare professional submitted a voluntary MedWatch report of a device malfunction.
Common Mistakes
- Treating safety signal reviews as periodic instead of continuous.
- Not linking new enforcement letters to internal CAPA and labeling workflows.
- Using static templates for dynamic benefit-risk communication updates.
Related Regulations
Frequently Asked Questions
For sponsors and manufacturers — yes, with specific timelines based on event severity and expectedness. For healthcare professionals and consumers — voluntary, though strongly encouraged. The Safety Reporting Portal and Form FDA 3500 are the primary submission channels.
FAERS (drugs and biologics), MAUDE (medical devices), VAERS (vaccines), and the CAERS system (cosmetics, foods, dietary supplements). FDA signal detection teams analyze these databases using statistical and clinical methods to identify emerging safety concerns.
Yes, in redacted form through FDA's FAERS and MAUDE public dashboards. Reporter identity and patient identifiers are removed. Researchers, sponsors, and the public can search these databases. FDA's internal safety analysis uses the full records with access controls.
Related Terms
Related Use Cases
Related Regulatory Intelligence
Related Actions
Track every sequence operation, amendment, and supplement across the product lifecycle.
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
Plan, validate, and execute active submissions in one workspace.
Sources & References
